宫颈癌治疗更新:妇科肿瘤学会临床实践声明
本文为妇科肿瘤学会临床实践声明,按治疗场景描述宫颈癌的化疗、放疗、免疫检查点阻断、抗血管生成及抗体药物偶联物等策略,并讨论生活质量、经济毒性与差异;复发性宫颈癌最佳治疗仍属未满足需求,须确保HPV疫苗、筛查和治疗的公平可及。
要点
- 宫颈癌治疗包括化疗、放疗、免疫检查点阻断、抗血管生成和抗体药物偶联物。
- 复发性宫颈癌最佳治疗仍是未满足需求,需探索细胞和免疫为基础的治疗。
- 有效治疗开发须结合策略确保HPV疫苗、筛查和治疗的普遍公平可及。
核心结论
- 复发性宫颈癌最佳治疗仍是未满足需求,需进一步探索合理创新的治疗方法,包括细胞和免疫为基础的治疗。
- 开发有效宫颈癌治疗必须纳入确保HPV疫苗、筛查和治疗普遍公平可及的策略。
研究设计与样本
- 本文为妇科肿瘤学会(Society of Gynecologic Oncology)临床实践声明,按治疗场景描述宫颈癌疗法,并讨论生活质量、经济毒性和差异。
主要发现
- 在高收入国家,随着筛查增加和HPV疫苗接种率提高,宫颈癌发病率已下降。
- 在低收入和中等收入国家,宫颈癌仍是女性癌症死亡的第二大原因。
- 宫颈癌患者经济毒性风险增加,可对躯体、经济和职业结局产生下游有害影响。
- 妇科肿瘤临床试验中种族和族裔少数群体代表性不足。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cervical cancer is the most commonly diagnosed gynecologic cancer worldwide. Although the incidence has declined with increased screening and higher uptake of human papillomavirus (HPV) vaccination in high-income countries, this disease remains the second highest cause of cancer mortality among women in low- and middle-income countries. In this clinical practice statement, we describe therapies for cervical cancer by treatment setting, as well as quality of life, financial toxicity, and disparities associated with this disease. In addition to chemotherapy and radiation, therapeutic strategies for cervical cancer include immune checkpoint blockade, antiangiogenics, and antibody-drug conjugates. Optimal treatment for recurrent cervical cancer remains an area of unmet need, necessitating further exploration of rational and innovative treatment approaches, including cell and immune-based therapies. Importantly, development of effective therapies for cervical cancer must incorporate strategies to ensure universal equitable access to HPV vaccination, screening, and treatment. Important consequences of the disease and treatment that impact quality of life must also be addressed. Patients with cervical cancer are at increased risk for financial toxicity, which can lead to downstream detrimental effects on physical, financial, and career outcomes. Underrepresentation of racial and ethnic minorities in gynecologic oncology clinical trials highlights the urgent need for collaborative and focused initiatives to bridge the significant divide and alleviate inequalities in the prevention and treatment of cervical cancer.
引用
- Girda E, Randall LM, Chino F, et al. Cervical cancer treatment update: A Society of Gynecologic Oncology clinical practice statement. Gynecol Oncol. 2023. PMID: 37980766. doi:10.1016/j.ygyno.2023.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。